PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 4356606

Transfer factor induced delayed hypersensitivity in X-linked combined immunodeficiency.

R M Goldblum·R A Lord·E Dupree·A G Weinberg·A S Goldman
View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Bone Marrow ExaminationCandidiasisConcanavalin ACytomegalovirus InfectionsFluorescent Antibody TechniqueHistocompatibility AntigensHumansHypersensitivity, DelayedImmune SeraImmunity, Maternally-AcquiredImmunoglobulinsImmunologic Deficiency SyndromesInfantLectinsLymph NodesLymphocyte ActivationMaleMitogensPalatine TonsilPedigreePneumonia, PneumocystisThymidineTritiumJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R M Goldblum, R A Lord, E Dupree, A G Weinberg, A S Goldman. 1973. Transfer factor induced delayed hypersensitivity in X-linked combined immunodeficiency.. https://doi.org/10.1016/0008-8749(73)90081-6

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Long-lasting partial remission by Interferon-alpha treatment in a child with essential thrombocythemia.

Essential thrombocythemia (ET) is a clonal myeloproliferative disorder characterized by sustained thrombocytosis, isolated hyperplasia of megakaryocytic lineage, and association with thrombotic or bleeding episodes. It is extremely rare in childhood and frequently presents without evident clinical signs. We describe a 3-year-old girl with severe headache and dizziness suffering from ET, who was treated with Interferon-alpha-2a (IFN) based on the potent effect of this agent to inhibit myeloid colonies induced by phytohemagglutinin A stimulated leukocyte conditioned medium (PHA-LCM). Bone-marrow-derived mononuclear cells of this patient did not exhibit spontaneous colony formation but responded to recombinant human (rh) erythropoietin (EPO), rh granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage (GM)-CSF, and stem-cell factor in addition to PHA-LCM. After 65 months of in vivo IFN treatment, the patient experienced a sustained partial remission with platelet counts varying between 400 and 600 x 10(3)/microl.

Bone Marrow Examination↗